Furthermore, several studies have found that other NF-κB inhibitors acting on the Tat-NEMO-binding domain, IKK-NEMO-binding domain, and the selective 5-lipoxygenase inhibitor, are involved in the therapy of brain injury, indicating their potential for AD treatment. Here, IKBKG is linked to Alzheimer disease.